Cigna modified MM 0284 for recurrent pregnancy loss diagnosis and treatment, effective September 26, 2025. Here's what billing teams need to do.
Cigna Healthcare updated its coverage policy for recurrent pregnancy loss (also documented as recurrent spontaneous abortion, or RSA) under policy MM 0284. The update draws a clear line between covered procedures—cervical cerclage codes CPT 57700 and 59325—and several services now explicitly designated as not medically necessary, including CPT 86950 (leukocyte transfusion), CPT 96365 (IV infusion), CPT 83520 (inhibitor immunoassay), and CPT 86357 (NK cell total count). If your practice bills for any of these six codes in the context of recurrent pregnancy loss treatment, this coverage policy change directly affects your claim outcomes starting September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Recurrent Pregnancy Loss: Diagnosis and Treatment |
| Policy Code | MM 0284 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | OB/GYN, Reproductive Endocrinology, Maternal-Fetal Medicine, Hematology, Clinical Immunology |
| Key Action | Audit charge capture for CPT 86950, 96365, 83520, and 86357 — these are now explicitly not medically necessary under this policy |
Cigna Recurrent Pregnancy Loss Coverage Criteria and Medical Necessity Requirements 2025
Recurrent pregnancy loss is a heterogeneous condition. Cigna acknowledges that RSA results from a range of underlying causes — anatomic, hormonal, thrombotic, autoimmune, alloimmune, genetic, and infectious. That clinical complexity is exactly what makes this coverage policy tricky to bill against.
Under MM 0284, Cigna considers cervical cerclage medically necessary when selection criteria are met. CPT 57700 covers nonobstetrical cerclage of the uterine cervix. CPT 59325 covers cerclage of the cervix during pregnancy via the abdominal approach. Both require documented medical necessity. If your documentation doesn't tie the procedure directly to the criteria in the applicable coverage position, expect a claim denial.
Prior authorization requirements for cerclage procedures aren't explicitly called out in the policy summary, but that doesn't mean you're clear. Always verify prior auth requirements at the plan level before scheduling. Cigna's individual and employer-sponsored plans can vary, and assuming no prior auth is required is a fast path to a denial you can't easily appeal.
The real issue with this policy update is what it says about the not-covered services. Cigna's designation of leukocyte transfusion (CPT 86950) and IV infusion therapy (CPT 96365) as not medically necessary in this context signals a firm stance against immunotherapy-based approaches to RSA treatment. Some practices have been billing these services under general infusion or immunology codes. This policy makes that harder to defend.
Cigna Recurrent Pregnancy Loss Exclusions and Non-Covered Indications
Four codes are explicitly designated as not medically necessary under MM 0284. This isn't a gray area — Cigna drew the line clearly.
CPT 86950 (leukocyte transfusion) is not medically necessary. This targets paternal leukocyte immunization, a controversial RSA treatment that lacks strong evidence support. Cigna's position here is consistent with what other major payers have held for years.
CPT 96365 (IV infusion for therapy, prophylaxis, or diagnosis — initial) is not medically necessary in this context. Practices billing IVIG infusion for RSA under this code need to flag this immediately. The reimbursement exposure is significant if you've been running these through without challenge.
CPT 83520 and CPT 86357 are not medically necessary when used to report inhibitor testing or NK cell counts in the RSA workup context. NK cell testing has gained traction in some reproductive immunology practices as part of pre-implantation workups. Cigna is not covering it here.
The bottom line: if you're using immunologic testing or immunotherapy as part of an RSA protocol and billing it to Cigna, this policy update is a direct warning. Adjust now or absorb the denials.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Cervical cerclage, nonobstetrical | Covered | CPT 57700 | Medical necessity criteria must be met; document thoroughly |
| Cervical cerclage during pregnancy, abdominal approach | Covered | CPT 59325 | Medical necessity criteria must be met; verify prior auth at plan level |
| Leukocyte transfusion for RSA | Not Covered | CPT 86950 | Explicitly not medically necessary under MM 0284 |
| IV infusion therapy for RSA | Not Covered | CPT 96365 | Explicitly not medically necessary; high denial risk if billed to Cigna |
| Inhibitor immunoassay (quantitative) for RSA workup | Not Covered | CPT 83520 | Not medically necessary when used to report inhibitor testing in RSA context |
| NK cell total count for RSA workup | Not Covered | CPT 86357 | Not medically necessary when used in RSA workup context |
Cigna Recurrent Pregnancy Loss Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit all open and recent claims containing CPT 86950, 96365, 83520, and 86357 billed to Cigna for RSA patients. Do this before the effective date of September 26, 2025. Claims submitted after that date under these codes in this clinical context will face denial. Claims already in process may also be affected depending on adjudication timing. |
| 2 | Update your charge capture and superbill to flag the four not-covered codes in RSA contexts. Don't leave it to your coders to catch at the claim level. Build a hard stop or a warning into your charge entry workflow for these codes when the diagnosis is recurrent pregnancy loss or recurrent spontaneous abortion. |
| 3 | Pull your documentation protocols for CPT 57700 and 59325 and confirm they meet Cigna's medical necessity criteria. These are your covered cerclage codes under MM 0284. If your documentation doesn't explicitly address the selection criteria Cigna references, cerclage claims will also be at risk. Covered doesn't mean automatically paid — it means payable when criteria are met. |
| 4 | Identify any Cigna patients currently in an RSA treatment protocol that includes immunotherapy or immunologic testing. Talk to your clinical team about how the September 26, 2025 effective date affects those treatment plans. The billing team shouldn't carry this conversation alone — loop in your medical director and, depending on volume, your compliance officer. |
| 5 | Review your recurrent pregnancy loss billing guidelines internally and update your payer-specific billing notes for Cigna. If your practice sees a significant volume of RSA patients with Cigna coverage, this policy warrants a formal internal update — not just a sticky note. Document when you made the change and what you changed it from. |
| 6 | For any claims denied on or after September 26, 2025 citing MM 0284, pull the medical records and confirm the denial basis before appealing. If Cigna is citing not-medically-necessary under this policy, an appeal requires clinical evidence that directly counters the coverage position. Appeals without that documentation won't move. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Recurrent Pregnancy Loss Under MM 0284
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 57700 | CPT | Cerclage of uterine cervix, nonobstetrical |
| 59325 | CPT | Cerclage of cervix, during pregnancy; abdominal |
Not Covered / Not Medically Necessary Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 86950 | CPT | Leukocyte transfusion | Considered not medically necessary under MM 0284 |
| 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to one hour | Considered not medically necessary under MM 0284 |
| 83520 | CPT | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative | Considered not medically necessary when used to report inhibitor testing in RSA context |
| 86357 | CPT | Natural killer (NK) cells, total count | Considered not medically necessary when used to report NK cell testing in RSA workup context |
No ICD-10-CM codes are listed in the MM 0284 policy data. Use the clinically appropriate RSA diagnosis codes from your standard coding resources and confirm they align with Cigna's covered indications above.
Get the Full Picture for CPT 57700
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.